CytoDyn
OTC: CYDYVancouver, US · Delaware corporation · 1 known investors
CytoDyn is a biopharmaceutical company conducting clinical trials, including a Phase 2 colorectal cancer trial.
Founders & leadership
RE
Robert E. HoffmanExecutive
JP
Jacob P. LalezariExecutive
TB
Tyler BlokExecutive
RM
Ryan M. DunlapExecutive
MD
Michael D. MulhollandExecutive
NZ
Nadar Z. PourhassanExecutive
AT
Andrew T. Libby, Jr.Executive
KJ
Kenneth J. Van NessExecutive
Board
JG
Jordan G. NaydenovBoard director
CC
Carl C. DockeryBoard director
TD
Tanya D. UrbachBoard director
SM
Stephen M. SimesBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$150.4M disclosed across 16 of 17 rounds · 2011–2026
▶$18.6MraisedMay 2026 · 194 investors · PharmaceuticalsRule 506(b)
▶$18.6MraisedMay 2026 · 194 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Tanya D. UrbachDirector
- Stephen M. SimesDirector
- Lishomwa C. Ndhlovu, M.D., Ph.D.Director
- Robert E. HoffmanExecutive Officer
- Jacob P. LalezariExecutive Officer
- Karen J. Brunke, Ph.D.Director
- Tyler BlokExecutive Officer
- Ryan M. DunlapDirector
- Offering amount
- $18.6M
- Amount sold
- $18.6M
- Minimum investment
- $15K
- Sales commissions
- $2.3M
- Proceeds to insiders
- $1.6M
- Placement agents
- Paulson Investment Company
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.8MraisedSep 2022 · 166 investors · PharmaceuticalsRule 506(c)
▶$21.8MraisedSep 2022 · 166 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Ryan DunlapDirector
- Scott A. KellyExecutive Officer, Director
- Arvin Cyrus ArmanExecutive Officer
- Karen J. BrunkeDirector
- Antonio MigliareseExecutive Officer
- Lishomwa C. NdhlovuDirector
- Tanya Durkee UrbachDirector
- Nitya G. RayExecutive Officer
- Offering amount
- $21.8M
- Amount sold
- $21.8M
- Minimum investment
- $5K
- Sales commissions
- $2.8M
- Proceeds to insiders
- $600K
- Placement agents
- Paulson Investment Company
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$11.4MraisedDec 2021 · 118 investors · BiotechnologyRule 506(b)
▶$11.4MraisedDec 2021 · 118 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antonio MigliareseExecutive Officer
- Christopher RecknorExecutive Officer
- Tanya Durkee UrbachDirector
- Harish SeethamrajuDirector
- Jordan G. NaydenovDirector
- Nitya G. RayExecutive Officer
- Nader Z. PourhassanExecutive Officer, Director
- Lishomwa C. NdhlovuDirector
- Scott A. KellyExecutive Officer, Director
- Offering amount
- $53.6M
- Amount sold
- $11.4M
- Minimum investment
- $10K
- Sales commissions
- $6.5M
- Placement agents
- Paulson Investment Company
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedSep 2021 · 6 investors · BiotechnologyRule 506(b)
▶$2.9MraisedSep 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott A Kelly, M.D.Executive Officer, Director
- Gordon A. GardinerDirector
- Nitya G. Ray, Ph.D.Executive Officer
- Nader Z. Pourhassan, Ph.D.Executive Officer, Director
- Samir R. Patel, M.D.Director
- Christopher Recknor, M.D.Executive Officer
- Antonio Migliarese, C.P.A.Executive Officer
- Alan P. TimminsDirector
- Jordan G. NaydenovDirector
- Offering amount
- $25.2M
- Amount sold
- $2.9M
- Minimum investment
- $250K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MofferedDec 2020 · BiotechnologyRule 506(b)
▶$1.2MofferedDec 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael D. MulhollandExecutive Officer
- Nitya G. Ray, Ph.D.Executive Officer
- Mahboob Rahman, M.D., Ph.D.Executive Officer
- Arian ColachisExecutive Officer
- Scott Kelly, M.D.Executive Officer, Director
- Alan P. TimminsDirector
- Jordan G. NaydenovDirector
- Nader Z Pourhassan, Ph.DExecutive Officer, Director
- Samir R. Patel, M.D.Director
- Offering amount
- $1.2M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedDec 2020 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedDec 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott Kelly, M.D.Executive Officer, Director
- Nader Z Pourhassan, Ph.DExecutive Officer, Director
- Jordan G. NaydenovDirector
- Alan P. TimminsDirector
- Samir R. Patel, M.D.Director
- Michael D. MulhollandExecutive Officer
- Nitya G. Ray, Ph.D.Executive Officer
- Mahboob Rahman, M.D., Ph.D.Executive Officer
- Arian ColachisExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- Minimum investment
- $1M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.6MraisedApr 2020 · 3 investors · BiotechnologyRule 506(b)
▶$7.6MraisedApr 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nader Z PourhassanExecutive Officer, Director
- David F WelchDirector
- Craig EastwoodExecutive Officer
- Alan P TimminsDirector
- Jordan G NaydenovDirector
- Arian ColachisExecutive Officer
- Scott A KellyDirector
- Offering amount
- $11.4M
- Amount sold
- $7.6M
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$882KraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$882KraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nader Z PourhassanExecutive Officer, Director
- Craig EastwoodExecutive Officer
- Jordan G NaydenovDirector
- Arian ColachisExecutive Officer
- Scott A KellyDirector
- David F WelchDirector
- Alan P TimminsDirector
- Offering amount
- $1.2M
- Amount sold
- $882K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
Seeking Alpha66 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Public56 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
StockTwits54 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Perplexity46 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
TipRanks44 shared keywordsFinancial analysis and stock research platform.
TradingView38 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall St32 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with CytoDyn for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Leronlimab solid-tumor data and $17.5M funding plan at CytoDyn (CYDY)stocktitan.net · Apr 2026Frequently asked questions
- What does CytoDyn do?
- CytoDyn is a biopharmaceutical company conducting clinical trials, including a Phase 2 colorectal cancer trial.
- Who are CytoDyn's investors?
- CytoDyn's investors include Yorkville Advisors.
- How much funding has CytoDyn raised?
- CytoDyn has disclosed $150.4M raised across 16 of its 17 known rounds.
- Where is CytoDyn headquartered?
- CytoDyn is headquartered in Vancouver, US.